+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating a blood-based test called Episwitch CiRT4 to see if it can predict how patients with stage III or IV cancer will respond to immune checkpoint inhibitor ICI treatments, specifically PD-L-1 inhibitors. This observational study aims to compare test predictions with actual patient responses across different types of cancer. The study also explores how social factors might relate to treatment responses and outcomes. Patients who are candidates for or currently receiving ICI therapy will undergo the Episwitch CiRT4 test before starting or during treatment. If the test indicates a high likelihood of response, repeat testing will occur every three months. Participants will be followed for six months to collect data on treatment administered, disease progression, survival, and patient-reported outcomes, along with social determinants of health. Throughout the study, researchers will gather clinical information, including physician questionnaires and patient feedback, to assess outcomes such as disease-free survival and time to recurrence. The study will also analyze health economics related to the tests potential to reduce unnecessary ICI treatments. Monitoring will continue for 24 weeks, with comprehensive data collection to evaluate the correlation between test results, social factors, and patient outcomes.

Age: 18Years +All Genders
3 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are studying the Caris Biorepository, a project designed to collect and store high-quality biological specimens and related clinical data to support research aimed at advancing precision medicine and improving patient care. This observational study focuses on gathering samples and information from various sources, including healthy individuals and cancer patients, to help understand disease treatments and clinical outcomes. The biorepository includes samples from different donor groups, such as those with no disease, treatment-nave patients with new solid tumors, individuals at higher risk for cancer, patients with advanced cancer, and those with a history of cancer but no active disease. The project aims to maintain molecular integrity and clinical relevance of these specimens while providing access to researchers and collaborators for drug development, clinical trials, and healthcare policy enhancements. Participants provide informed consent and contribute biological samples and clinical data that are securely stored and shared for research purposes. The study measures include ensuring specimen quality and relevance over 35 years and facilitating specimen release for testing. Laboratory testing will be conducted throughout the study duration. The project supports long-term research collaboration and aims to impact patient outcomes and treatment practices over time.

Age: 18Years +All Genders
38 locations
E

Actively Recruiting

This research aims to evaluate whether combining medications for alcohol use disorder MAUD with a smartphone app called Stand Down SD-App improves drinking outcomes among Veterans compared to medications alone. The study addresses common barriers to treatment such as wait times, stigma, and distance from care, focusing on Veterans receiving primary care. It also explores factors affecting the apps adoption and sustainability in VA primary care settings. Participants will be randomly assigned to one of two groups one receiving standard MAUD care prescribed by clinical pharmacists, and the other receiving MAUD plus access to the SD-App. The app supports self-management by helping users monitor drinking, set goals to moderate or abstain, manage cravings, and connect with support. The study includes Veterans aged 18 to 80 diagnosed with alcohol use disorder and planning to start MAUD. Throughout the study, participants will complete assessments at baseline, 3, 6, and 12 months, including self-reports and medical record reviews. Researchers will measure changes in heavy drinking days, alcohol-related consequences, risk levels, mental health, and satisfaction. Qualitative interviews will gather perspectives on the interventions use. The total study duration spans up to 12 months post-baseline, with ongoing monitoring to inform wider implementation of the app across VA primary care.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
15 locations
S

Actively Recruiting

Researchers are evaluating the performance of two blood-based diagnostic aid tests designed to detect cancer in individuals aged 45 and older who show symptoms, signs, or findings that suggest possible cancer. The study focuses on cancers originating from specific sites as outlined in the protocol, aiming to establish how well these tests identify the presence of cancer compared to standard diagnostic methods. Participants will provide a blood sample for analysis by the investigational diagnostic tests. The study includes people either undergoing diagnostic work-up for suspected cancer or those recently diagnosed with cancer who have not yet received treatment. The test results will be kept blinded from investigators, clinicians, and participants, ensuring that the investigational test does not influence clinical decisions. All analyses will be done without revealing results during the study period. During the study, participants will have blood collected and undergo standard diagnostic procedures as recommended by their doctors. The research team will gather clinical outcomes based on routine care diagnostics and pathology reports. Researchers will measure how accurately the tests detect cancer and assess various test readout distributions over an 18-month period. Participants involvement includes consenting to blood draws and allowing access to diagnostic information, with no additional interventions affecting their usual care.

Age: 45Years +All Genders
42 locations